Protochemotherapy in non-small cell lung carcinoma. An attempt to increase surgical resectability and survival. A preliminary report
Open Access
- 1 January 1986
Abstract
Twenty patients with Stage IIIM0 (T3N2) non-small cell lung cancer were treated with vindesine, etoposide, and Platinol (cisplatin) (ELETOP) chemotherapy in an attempt to decrease tumor size and increase resectability and survival. ELETOP chemotherapy induced a 70% response rate (all partial responses) within 6 weeks, and three patients were able to undergo curative resection. Toxicities with ELETOP were moderately severe, with leukocyte and platelet nadirs on day 15. This pilot study demonstrates the feasibility of protochemotherapy in non-small cell lung cancer.This publication has 11 references indexed in Scilit:
- Combined modality therapy for stage IIIMO non-small cell lung cancer. A five-year experienceCancer, 1984
- Phase I and pharmacologic evaluation of nafazatrom in patients with cancerInvestigational New Drugs, 1984
- Adjuvant chemotherapy with Cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neckCancer, 1983
- Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lungThe Journal of Thoracic and Cardiovascular Surgery, 1982
- THORACIC RADIATION-THERAPY AND ADRIAMYCIN-CISPLATIN-CONTAINING CHEMOTHERAPY FOR LOCALLY ADVANCED NON-SMALL-CELL LUNG-CANCER1981
- Irradiation for inoperable carcinoma of the lung and high performance statusJAMA, 1980
- Sequential Staging in Bronchogenic CarcinomaChest, 1979
- Assessment of the Role of Surgery for Control of Lung CancerThe Annals of Thoracic Surgery, 1977